JPWO2017157322A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2017157322A5
JPWO2017157322A5 JP2018548895A JP2018548895A JPWO2017157322A5 JP WO2017157322 A5 JPWO2017157322 A5 JP WO2017157322A5 JP 2018548895 A JP2018548895 A JP 2018548895A JP 2018548895 A JP2018548895 A JP 2018548895A JP WO2017157322 A5 JPWO2017157322 A5 JP WO2017157322A5
Authority
JP
Japan
Prior art keywords
group
substituted
unsubstituted
acid
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018548895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515878A (ja
JP2019515878A5 (https=
JP7605579B2 (ja
Publication date
Priority claimed from CN201610149958.6A external-priority patent/CN107200706A/zh
Application filed filed Critical
Publication of JP2019515878A publication Critical patent/JP2019515878A/ja
Publication of JP2019515878A5 publication Critical patent/JP2019515878A5/ja
Publication of JPWO2017157322A5 publication Critical patent/JPWO2017157322A5/ja
Application granted granted Critical
Publication of JP7605579B2 publication Critical patent/JP7605579B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018548895A 2016-03-16 2017-03-16 フッ素置換シクロプロピルアミン系化合物並びにその製造方法、薬物組成物及び使用 Active JP7605579B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610149958.6 2016-03-16
CN201610149958.6A CN107200706A (zh) 2016-03-16 2016-03-16 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
PCT/CN2017/076967 WO2017157322A1 (zh) 2016-03-16 2017-03-16 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途

Publications (4)

Publication Number Publication Date
JP2019515878A JP2019515878A (ja) 2019-06-13
JP2019515878A5 JP2019515878A5 (https=) 2022-03-09
JPWO2017157322A5 true JPWO2017157322A5 (https=) 2022-03-09
JP7605579B2 JP7605579B2 (ja) 2024-12-24

Family

ID=59850098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018548895A Active JP7605579B2 (ja) 2016-03-16 2017-03-16 フッ素置換シクロプロピルアミン系化合物並びにその製造方法、薬物組成物及び使用

Country Status (9)

Country Link
US (1) US10836743B2 (https=)
EP (1) EP3431471A4 (https=)
JP (1) JP7605579B2 (https=)
KR (1) KR102196050B1 (https=)
CN (2) CN107200706A (https=)
CA (1) CA3021608C (https=)
RU (1) RU2746323C9 (https=)
SG (1) SG11201808017PA (https=)
WO (1) WO2017157322A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102479789B1 (ko) 2016-05-09 2022-12-22 주빌런트 에피코어 엘엘씨 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물
CN107459476B (zh) * 2016-06-03 2022-06-24 中国科学院上海药物研究所 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
RU2763898C9 (ru) * 2017-01-24 2022-03-18 Цспц Чжунци Фармасьютикал Текнолоджи (Шицзячжуан) Ко., Лтд. Ингибитор lsd1, а также способ его получения и его применение
MX2020001323A (es) 2017-08-03 2020-03-20 Oryzon Genomics Sa Metodos para tratar alteraciones del comportamiento.
CN109321940A (zh) * 2018-11-30 2019-02-12 西南大学 一种酰胺的电化学氧化合成方法及其应用
SG11202109159VA (en) 2019-03-20 2021-10-28 Oryzon Genomics Sa Methods of treating borderline personality disorder
ES3053813T3 (en) 2019-03-20 2026-01-26 Oryzon Genomics Sa Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
CN114341366A (zh) 2019-07-05 2022-04-12 奥莱松基因组股份有限公司 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法
CN112939846B (zh) * 2019-11-26 2023-12-26 中国科学院上海药物研究所 一种乙酰胆碱酯酶抑制剂的晶型及其制备方法和应用
JP2024513260A (ja) 2021-04-08 2024-03-22 オリゾン ジェノミックス ソシエダッド アノニマ 骨髄癌処置のためのlsd1阻害剤の組み合わせ
CN119546292A (zh) 2022-05-09 2025-02-28 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗恶性周围神经鞘瘤(mpnst)的方法
JP2025516648A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Lsd1阻害薬を用いるnf1変異腫瘍の治療法
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
CN118239883A (zh) * 2022-12-22 2024-06-25 江苏联环药业股份有限公司 一类赖氨酸特异性脱甲基酶1(lsd1)抑制剂的制备方法
CN118787751A (zh) * 2023-04-12 2024-10-18 中国科学院上海药物研究所 Lsd1抑制剂与药物联用治疗癌症的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55348B1 (sr) 2010-04-19 2017-03-31 Oryzon Gnomics S A Inhibitori lizin specifične demetilaze-1 i njihova upotreba
WO2012013728A1 (en) * 2010-07-29 2012-02-02 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
EA023143B1 (ru) 2011-03-25 2016-04-29 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Замещенный циклопропиламин в качестве ингибитора lsd1
RU2668952C2 (ru) 2011-10-20 2018-10-05 Оризон Дженомикс, С.А. (гетеро)арилциклопропиламины в качестве ингибиторов lsd1
MX356344B (es) 2011-10-20 2018-05-23 Oryzon Genomics Sa Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1.
MX373103B (es) * 2014-02-13 2020-04-17 Incyte Holdings Corp Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
SI3105218T1 (sl) 2014-02-13 2019-11-29 Incyte Corp Ciklopropilamini kot inhibitorji LSD1
EP3105219B9 (en) * 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) * 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors

Similar Documents

Publication Publication Date Title
JPWO2017157322A5 (https=)
JP2019515878A5 (https=)
TWI405754B (zh) 芳基取代之磺醯胺化合物及其作為抗癌劑之用途
ES2435070T3 (es) Derivados de estilbeno y su uso para unión y formación de imágenes de placas amiloides
KR100860655B1 (ko) 칼슘 수용체 활성 화합물
JP2022518591A (ja) 複素環式化合物であるベンゾピリドンおよびその使用
RU2018136336A (ru) Фторированное соединение циклопропиламина, способ получения, фармацевтическая композиция и ее использование
ES2718379T3 (es) Derivado de ácido 4-aminometilbenzoico
CN110139863B (zh) 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
JPWO2020094104A5 (https=)
JP2022537605A (ja) Crbnタンパク質モジュレーターとしての二環式化合物
Müller et al. Synthesis and N‐Methyl‐d‐aspartate (NMDA) Antagonist Properties of the Enantiomers of α‐Amino‐5‐(phosphonomethyl)[1, 1′‐biphenyl]‐3‐propanoic Acid. Use of a New Chiral Glycine Derivative
CH623321A5 (en) Process for the preparation of heterocyclic aminoalcohol derivatives
ES2842448T3 (es) Compuesto de sultama y método de aplicación del mismo
RU2007121697A (ru) Гидроксибензоатные соли метаникотиновых соединений
CN112513011B (zh) 苯衍生物
KR20180128456A (ko) 에스트로겐 수용체 하향 조절제로서의 치환된 인돌 화합물
EP3400210B1 (fr) Composés"multi-cibles"à activité inhibitrice des histone-désacétylases et de la polymérisation de la tubuline pour son utilisation dans le traitement du cancer
CN102516152A (zh) 一种α-二氟羰基取代的手性叔醇类化合物及其合成方法和应用
BR112018072869B1 (pt) Compostos de s-triazina 2,4,6-trissubstituídos, seus usos, e composição farmacêutica
US5171752A (en) Benzhydryl derivatives having calmodulin inhibitor properties
JP2021509399A (ja) インドールアミン−2,3−ジオキシゲナーゼ阻害剤およびその調製方法と使用
Sapegin et al. A novel, flexible strategy to construct privileged dibenzo [b, f][1, 4, 5] oxathiazepine 5, 5-dioxides and their heterocyclic isosteres
JP5302214B2 (ja) Trpv1受容体拮抗薬としてのo−置換ジベンジル尿素誘導体
BG63367B1 (bg) Нитробензамиди, полезни като противоаритмични средства